Suppr超能文献

经化疗栓塞治疗的肝细胞癌的放射病理相关性。

Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.

机构信息

Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair, Suite 800, Chicago, IL 60611, USA.

出版信息

Cardiovasc Intervent Radiol. 2010 Dec;33(6):1143-52. doi: 10.1007/s00270-009-9766-5. Epub 2009 Dec 5.

Abstract

To correlate posttreatment radiologic and pathologic findings in patients who underwent transarterial chemoembolization before transplantation or resection. Thirty-five patients with postchemoembolization follow-up imaging underwent liver transplantation/resection. Pre- and posttreatment contrast-enhanced magnetic resonance imaging were used to evaluate radiologic findings. Imaging characteristics using World Health Organization (WHO) and European Association for the Study of the Liver (EASL) criteria after treatment were evaluated. Treated lesions were examined by pathology (gold standard) for the assessment of necrosis. Radiologic findings on magnetic resonance imaging were correlated to pathologic findings to assess the predictability by imaging of actual necrosis. Kappa (κ) statistics were used to determine intermethod agreement between WHO and EASL criteria. Fourteen (40%) of 35 lesions had biopsy-proven hepatocellular carcinoma. Thirteen (37%) of 35 target lesions showed complete pathologic necrosis. Complete pathologic necrosis was seen in 35% of lesions with pretreatment size <3 cm. Complete pathologic necrosis was seen in 1 (100%) of 1, 6 (67%) of 9, 6 (33%) of 18, and 0 (0%) of 7 of the lesions that exhibited complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) by WHO criteria, respectively. Complete pathologic necrosis was seen in 9 (82%) of 11, 4 (36%) of 11, 0 (0%) of 8, and 0 (0%) of 5 of the lesions that showed CR, PR, SD, or PD by EASL criteria, respectively. EASL CR and WHO response were shown to have ≥85% specificity for predicting complete pathologic necrosis. The κ coefficient for agreement between WHO and EASL was 0.29. EASL and WHO criteria had minimal intermethod agreement. EASL CR and WHO response were able to predict pathologic necrosis.

摘要

为了在接受肝移植或切除术前进行经动脉化疗栓塞治疗的患者中,对治疗后影像学和病理学发现进行相关性分析。35 例经化疗栓塞治疗后随访影像学的患者接受了肝移植/切除。使用磁共振成像(MRI)平扫和增强扫描评估患者影像学表现,采用世界卫生组织(WHO)和欧洲肝脏研究协会(EASL)标准评估治疗后影像特征。通过病理学(金标准)检查治疗后的病变,以评估坏死的实际情况。通过 MRI 影像学表现与病理学结果进行相关性分析,评估影像学对实际坏死的预测能力。采用 Kappa(κ)统计量评估 WHO 和 EASL 标准之间的方法学一致性。35 个病灶中,有 14 个(40%)经活检证实为肝细胞癌。35 个靶病灶中,有 13 个(37%)完全坏死。治疗前直径<3cm 的病灶完全坏死率为 35%。在符合 WHO 完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和进展(PD)标准的病变中,完全坏死率分别为 100%(1/1)、67%(6/9)、33%(6/18)和 0%(0/7)。在符合 EASL CR、PR、SD 和 PD 标准的病变中,完全坏死率分别为 82%(9/11)、36%(4/11)、0%(0/8)和 0%(0/5)。EASL CR 和 WHO 反应的特异性均≥85%,可以预测完全坏死。WHO 和 EASL 标准之间的κ系数为 0.29,两者之间的一致性较差。EASL CR 和 WHO 反应可以预测病理学坏死。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2b2/2921465/5fbde6a2f150/nihms200456f1.jpg

相似文献

引用本文的文献

本文引用的文献

5
Design and endpoints of clinical trials in hepatocellular carcinoma.肝细胞癌临床试验的设计与终点
J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.
6
Diagnosis and treatment of hepatocellular carcinoma.肝细胞癌的诊断与治疗
Gastroenterology. 2008 May;134(6):1752-63. doi: 10.1053/j.gastro.2008.02.090.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验